Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/8688
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Acheampong, Desmond O. | - |
dc.contributor.author | Adokoh, Christian K. | - |
dc.contributor.author | Ampomah, Paulina | - |
dc.contributor.author | Agyirifo, Daniel S. | - |
dc.contributor.author | Dadzie, Isaac | - |
dc.contributor.author | Ackah, Francis A. | - |
dc.contributor.author | Asiamah, Ernest A. | - |
dc.date.accessioned | 2023-09-29T10:51:14Z | - |
dc.date.available | 2023-09-29T10:51:14Z | - |
dc.date.issued | 2017 | - |
dc.identifier.uri | http://hdl.handle.net/123456789/8688 | - |
dc.description.abstract | Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and ra- diotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate per- petual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibod- ies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique char- acteristics. This review discusses up to date therapeutic potentials of BsAbs. | en_US |
dc.language.iso | en | en_US |
dc.publisher | University of Cape Coast | en_US |
dc.subject | Antibody | en_US |
dc.subject | bispecific antibody (BsAb), | en_US |
dc.subject | immunotherapeutic agent | en_US |
dc.subject | cancer therapy | en_US |
dc.subject | diabody | en_US |
dc.subject | antitumor | en_US |
dc.title | Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Allied Health Sciences |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bispecific Antibodies (bsAbs)Promising Immunotherapeutic Agents for.pdf | Main Article | 807.89 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.